KALLELSE TILL ÅRSSTÄMMA I XNK THERAPEUTICS AB

Aktieägarna i XNK Therapeutics AB (publ), org.nr 556894–6601, kallas härmed till årsstämma tisdagen den 13 juni 2023 kl. 17.00 i bolagets lokaler, Novum, plan 8 (hiss E), Hälsovägen 7,…

XNK Receives EU Tissue Establishment Certificate

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control of the complete manufacturing chain, from withdrawal of blood from the patient at the clinic to the delivery of the finished autologous NK-cell based medicinal product.

XNK Therapeutics appoints Dr. Peter Hovstadius as CMO

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr. Hovstadius will be a member of the company’s management team. Dr. Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor.